Novartis licenses CMV vaccine from AlphaVax

AlphaVax (Research Triangle Park, N.C.) granted Novartis (NYSE:NVS; SWX:NOVN) exclusive, worldwide rights to develop and commercialize a vaccine to prevent cytomegalovirus (CMV) infection. The vaccine...